Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Area of Science:

• Pharmacology and Therapeutics
• Cardiovascular Risk Assessment
• Infectious Disease Management

Background:

• Azithromycin and levofloxacin are commonly used antibiotics with established efficacy.
• Previously considered rare, potential adverse drug events include QT prolongation, as warned by the US FDA.
• Understanding the cardiovascular risks associated with these antibiotics is crucial for patient safety.

Purpose of the Study:

• To critically review existing literature on the cardiovascular risks of azithromycin and levofloxacin.
• To synthesize findings from various study designs, including case reports, observational studies, and clinical trials.
• To inform clinical decision-making regarding the use of these antibiotics.

Main Methods:

• Systematic review of 15 case reports/series, 5 observational studies, and 5 clinical trials.
• Focus on studies assessing cardiovascular risks, specifically QT prolongation and cardiovascular death.
• Critical appraisal of evidence to evaluate the association between antibiotic use and cardiac events.

Main Results:

• Conflicting evidence exists regarding the cardiovascular risks of azithromycin.
• Some studies suggest an increased risk of cardiovascular death with azithromycin compared to amoxicillin, while others show no difference.
• Limited evidence suggests a potential increased risk of cardiovascular death with levofloxacin in one retrospective study.

Conclusions:

• The risk-benefit profile of azithromycin and levofloxacin requires careful consideration in clinical practice.
• While potential risks exist, these antibiotics may still be prescribed when indicated, provided risks are understood.
• Further research may be needed to clarify the definitive cardiovascular risks associated with these widely used antibiotics.